Table 1.
Abbreviations: ACEi/ABR blockers: angiotensin converting enzyme inhibitors/angiotensin receptor blockers; BMI: body mass index; BNP: brain natriuretic peptide; BUN: blood urea nitrogen; Cr: creatinine; Hb: hemoglobin, Na: serum sodium.
| Group 1 (RDW > 14.5%) 117 patients | Group 2 (RDW ≤ 14.5%) 174 patients | P value | |
|---|---|---|---|
| Age (mean) | 61 ± 13 years | 62 ± 14 years | 0.6 |
| Male gender | 79 | 120 | 0.8 |
| Race | < 0.0001 | ||
| Caucasians | 38 (33%) | 75(43%) | |
| Hispanics | 23 (20%) | 60 (35%) | |
| Blacks | 56 (47%) | 39(22%) | |
| Diabetes | 49 | 71 | 0.9 |
| Hypertension | 94 | 122 | 0.06 |
| Dyslipidemia | 55 | 80 | 0.9 |
| Smoking | 57 | 70 | 0.16 |
| BMI (kg/m2) | 28 (25–32) | 28 (25–32) | 0.4 |
| Symptoms of CHF | 73 | 47 | < 0.0001 |
| Atrial fibrillation | 25 | 22 | 0.08 |
| Cr (mg/dl) | 0.9 (0.8–1.1) mg/dl | 1.1 (0.9–1.3) mg/dl | < 0.0001 |
| BUN (mg/dl) | 14 (11–18) | 16 (12–24) | 0.005 |
| Na (meq/dl) | 137 (136–140) meq/dl | 137(136–140) | 0.38 |
| BNP (pg/ml) | 907 (252–1923) | 348 (128–676) | < 0.0001 |
| Hb (gm/dl) | 13.3 (12.3–14.2) | 14 (12.7–14.9) | 0.003 |
| Medications | |||
| Beta blockers | 52 | 76 | 0.9 |
| ACEi./ARB Blockers | 70 | 75 | 0.006 |
| Statins | 41 | 65 | 0.7 |
| Diuretics | 41 | 48 | 0.07 |
| Digoxin | 17 | 9 | 0.005 |
| warfarin | 11 | 11 | 0.3 |